Following the annual audit and constructive discussions with our auditor, accounting adjustments were made to Eevia's statutory financial accounts for 2023 released on
The Year-End Report recognized revenue that, due to an agreed mid-shipment change of delivery terms, resulted in revenue of approximately 263 kEUR being recognized in
Due to the adjustments in the financial accounts for 2023, the figures for first quarter 2024 also changed. The adjustments increased the sales revenues recognized in Q1-2024 and improved the EBITDA for this quarter. Therefore, Eevia now restates the Interim Report for Q1-2024.
Financial developments and significant events in the first quarter of 2024
- Net sales[1] increased to KEUR 407 in Q1-24 from KEUR 317 in Q4-23. However, adjusted for product returns in Q4-23, Net sales decreased from KEUR 560. Compared to Q1-23, net sales were down by KEUR 1 393 from KEUR 1 710.
- Gross profit in Q1-24 was KEUR 263, a decrease of 26% from KEUR 355 in Q4-23 and 73% from KEUR 989 in Q1-23. The gross margin was 65% in Q1-24, up from 63% in Q4-23 and up from 58% in Q1-23. The improvement since Q4-23 is due to a changing product mix.
- EBITDA in Q1-24 was KEUR - 212 compared to KEUR - 148 in Q4-23 and positive KEUR 260 in Q1-23. The reduction in EBITDA between Q4-23 and Q1-23 of KEUR 39 mainly stemmed from higher other incomes in Q4-23.
- The net result for Q1-24 was negative with KEUR - 487 compared to KEUR - 388 in Q4-23 and KEUR 17 in Q1-23.
- Cash flow from operations was negative with KEUR - 254 in Q1-24 compared to positive KEUR 115 in Q4-24, and KEUR 162 in Q1-23. The decrease in operating cash flow stems primarily from changes in working capital in the period and negative EBITDA.
- Eevia is in discussions with a global market leader in vision enhancement and eye-health about a possible collaboration related to the launch of Retinari®, Eevia's game-changing and novel eye-health product.
- Eevia secured a credit line from three Swedish investors of KEUR 640, of which Eevia drew KEUR 265 in Q1-24.
- Eevia started negotiations on a contract manufacturing arrangement for 2025 with an option to extend it to 2026 and 2027 with a mid-sized European food company. The parties expect to finalize discussions by the end of the second quarter 2024.
-
Eevia filed the final report to Business Finland for a project awarded a business development grant of KEUR 242 in
February 2023 . For costs expensed in 2023, Eevia received the payment of the grant inMarch 2024 .
[1] Sales revenues excluding trading revenues.
For further information, please contact:
Email: stein.ulve@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
To learn more, please visit www.eeviahealth.com or follow
https://news.cision.com/eevia-health/r/correction--eevia-health-publishes-restated-interim-report-q1-2024,c3999652
https://mb.cision.com/Main/20679/3999652/2860477.pdf
https://mb.cision.com/Public/20679/3999652/b7c952eaac0329be.pdf
(c) 2024 Cision. All rights reserved., source